Safety Strategies For Hypoimmune Cells

Tech ID: 34315 / UC Case 2026-046-0

Engineered, hypoimmune cells evade the immune system and can be used

for cell replacement therapies as well as immune-oncology therapies.

However, their immune evasiveness may be seen as a risk factor for

uncontrolled growth in the absence of immune surveillance. Safety

strategies that could selectively target hypoimmune cells and eliminate

them effectively could add additional safety to hypoimmune approaches.

Cell therapy

Pharmaceutical and biotech

Patent Pending